Applied Molecular Transport (Applied Molecular Transport) Net Income (Continuing Operations) : $-74.79 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Applied Molecular Transport Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Applied Molecular Transport's Net Income (Continuing Operations) for the three months ended in Sep. 2023 was $-6.94 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $-74.79 Mil.

Applied Molecular Transport Net Income (Continuing Operations) Historical Data

The historical data trend for Applied Molecular Transport's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Molecular Transport Net Income (Continuing Operations) Chart

Applied Molecular Transport Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income (Continuing Operations)

-29.87

-28.04

-66.56

-100.29

-126.33

Applied Molecular Transport Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-25.21	-22.60	-27.92	-17.33	-6.94

Applied Molecular Transport Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-74.79 Mil.

Applied Molecular Transport (NAS:AMTI) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Applied Molecular Transport Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Applied Molecular Transport's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Molecular Transport (Applied Molecular Transport) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Molecular Transport Inc (NAS:AMTI) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East Jamie Court, South San Francisco, CA, USA, 94080

Website

https://www.appliedmt.com

Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.

Executives

Shawn Cross	officer: Chief Financial Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Mahmood Tahir Ph.d.	director, officer: Chief Executive Officer	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Brandon Hants	officer: VP, Finance & Bus. Ops.	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Douglas A. Rich	officer: Chief Technical Officer	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Bittoo Kanwar	officer: Chief Medical Officer	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Mrsny Randall Ph.d.	director, officer: Chief Scientific Officer	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Aaron Vandevender	director	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
David Lamond	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Epiq Capital Group, Llc	other: Managing member of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Chad Boeding	other: CEO of Managing Member	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Charlene A. Banard	director	C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
John W Smither	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Epq Llc Amt Ps	other: Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtc Ps	other: Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtb Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521